Loading
A phase 2 trial of Pacritinib in chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, run by Theradex, now recruiting.
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia is a phase 2 interventional study registered as NCT07033598 by Theradex, with 66 participants planned, started 2026-01-01 and due to reach its primary completion in 2028-07. Interventions recorded: Pacritinib and Hydroxyurea.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sobi (Swedish Orphan Biovitrum) and the tag pipeline.
Shares Sobi (Swedish Orphan Biovitrum) and the tag pipeline.
Shares Sobi (Swedish Orphan Biovitrum) and the tag pipeline.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Small-molecule kinase inhibitors and the tag pipeline.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms and the tag pipeline.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms and the tag pipeline.
Shares Small-molecule kinase inhibitors and the tag pipeline.
Shares Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/